3,698 results match your criteria Imaging in Prostate Carcinoma


PET imaging in renal cancer.

Curr Opin Oncol 2019 Feb 11. Epub 2019 Feb 11.

Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Denmark.

Purpose Of Review: Worldwide, over 400 000 new cases of kidney cancer were diagnosed and over 175 000 deaths anticipated in 2018. It is ranked as the 14th most common cancer in women and 9th most common in men. Imaging is important for initial detection, staging, and monitoring to assist treatment planning, but conventional anatomic imaging is limited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000518DOI Listing
February 2019
2 Reads

Tumor-Specific S/G-Phase Cell Cycle Arrest of Cancer Cells by Methionine Restriction.

Methods Mol Biol 2019 ;1866:49-60

AntiCancer, Inc., San Diego, CA, USA.

Cancer cells require elevated amounts of methionine (MET) and arrest their growth under conditions of MET restriction (MR). This phenomenon is termed MET dependence. Fluorescence-activated cell sorting (FACS) first indicated that the MET-dependent SV40-transformed cancer cells were arrested in the S and G phases of the cell cycle when under MR. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/978-1-4939-8796-2_5
Publisher Site
http://dx.doi.org/10.1007/978-1-4939-8796-2_5DOI Listing
January 2019
8 Reads

Differentiating intrapulmonary metastases from different primary tumors via quantitative dual-energy CT based iodine concentration and conventional CT attenuation.

Eur J Radiol 2019 Feb 14;111:6-13. Epub 2018 Dec 14.

Department of Diagnostic and Interventional Radiology, Klinikum rechts der Isar, Technical University of Munich, Germany.

Introduction: To investigate the utility of quantitative dual-energy spectral CT derived iodine concentration (IC), in comparison with conventional CT attenuation, for the differentiation of pulmonary metastases from different primary malignancies.

Materials And Methods: CT scans were performed on a dual-layer spectral CT. We retrospectively evaluated pulmonary metastases of 130 patients (77 men and 53 women, mean age 63, range 22-87) with primary bone (OS) (osteosarcoma; n = 6), breast (invasive-ductal adenocarcinoma; n = 17), colorectal (CRC) (adenocarcinoma; n = 27), head and neck (HNC) (squamous cell carcinoma; n = 17), kidney (RCC) (clear-cell renal cell carcinoma; n = 10), lung (adenocarcinoma; n = 12), pancreato-biliary (PBC) (adenocarcinoma; n = 18), prostate (adenocarcinoma; n = 5), soft tissue (undifferentiated pleomorphic sarcoma; n = 6), skin (malignant melanoma; n = 6), and urinary tract (transitional-cell carcinoma; n = 6) malignancies. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0720048X183045
Publisher Site
http://dx.doi.org/10.1016/j.ejrad.2018.12.015DOI Listing
February 2019
6 Reads

Trousseau syndrome in a patient with advanced oral squamous cell carcinoma: a case report.

J Med Case Rep 2019 Jan 29;13(1):26. Epub 2019 Jan 29.

Department of Oral and Maxillofacial Surgery, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.

Background: Trousseau syndrome is known as a variant of cancer-associated thrombosis. Trousseau syndrome commonly occurs in patients with lung or prostate cancer. Hypercoagulability is thought to be initiated by mucins produced by the adenocarcinoma, which react with leukocyte and platelet selectins to form platelet-rich microthrombi. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13256-018-1833-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350311PMC
January 2019
1 Read

Imaging of Prostate-Specific Membrane Antigen with Small-Molecule PET Radiotracers: From the Bench to Advanced Clinical Applications.

Annu Rev Med 2019 Jan;70:461-477

The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA; email: ,

In recent years, small-molecule inhibitors of prostate-specific membrane antigen (PSMA) labeled with radionuclides that allow for positron emission tomography (PET) imaging have been extensively studied in many clinical contexts in men with prostate cancer (PCa). The high sensitivity and specificity of these agents for identifying sites of PCa has quickly led to their widespread adoption as a de facto clinical standard of care throughout much of the world. PSMA-targeted PET radiotracers have been particularly well-studied in preoperatively staging men with high-risk PCa, evaluating biochemical recurrence following definitive therapy, and guiding metastasis-directed therapy in patients suspected of having oligorecurrent/oligometastatic disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1146/annurev-med-062117-073027DOI Listing
January 2019
4 Reads

Molecular Hallmarks of Multiparametric Magnetic Resonance Imaging Visibility in Prostate Cancer.

Eur Urol 2019 Jan 24. Epub 2019 Jan 24.

Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA, USA; Institute of Urologic Oncology, University of California, Los Angeles, CA, USA; Department of Urology, David Geffen School of Medicine, 300 Stein Plaza, Los Angeles, CA 90095, USA. Electronic address:

Multiparametric magnetic resonance imaging (mpMRI) has transformed the management of localized prostate cancer by improving identification of clinically significant disease at diagnosis. Approximately 20% of primary prostate tumors are invisible to mpMRI, and we hypothesize that this invisibility reflects fundamental molecular properties of the tumor. We therefore profiled the genomes and transcriptomes of 40 International Society of Urological Pathology grade 2 tumors: 20 mpMRI-invisible (Prostate Imaging-Reporting and Data System [PI-RADS] v2 <3) and 20 mpMRI-visible (PI-RADS v2 5) tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.12.036DOI Listing
January 2019
1 Read

Positive effect of Actinium 225-PSMA treatment on ECOG performance status: A case report on a patient with castration resistant stage IV prostate carcinoma.

Rev Esp Med Nucl Imagen Mol 2019 Jan 18. Epub 2019 Jan 18.

International Atomic Energy Agency, Nuclear Medicine and Diagnostic Imaging Section, Viena, Austria. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S2253654X183015
Publisher Site
http://dx.doi.org/10.1016/j.remn.2018.09.003DOI Listing
January 2019
2 Reads

Effectiveness of the combination of vascular targeted photodynamic therapy and anti-cytotoxic T-lymphocyte-associated antigen 4 in a preclinical mouse model of urothelial carcinoma.

Int J Urol 2019 Jan 18. Epub 2019 Jan 18.

Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.

Objective: To investigate the effectiveness of combination treatment of vascular targeted photodynamic therapy and anti-cytotoxic T-lymphocyte-associated antigen 4 immunotherapy in a mouse model of urothelial carcinoma.

Methods: We used C57BL/6 mice injected with murine bladder 49 cell line. Mice were randomly allocated into four treatment groups: vascular targeted photodynamic therapy only, anti-cytotoxic T-lymphocyte-associated antigen 4 only, combination therapy and control. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/iju.13878
Publisher Site
http://dx.doi.org/10.1111/iju.13878DOI Listing
January 2019
4 Reads

Basal cell carcinoma of the prostate: A case report and review of the literature.

Mol Clin Oncol 2019 Jan 30;10(1):101-104. Epub 2018 Oct 30.

Department of Urology, Nankai Medical Center, Saiki, Oita 876-0857, Japan.

Basal cell carcinoma (BCC) of the prostate is a rare tumor exhibiting various morphological characteristics, and its progression varies from an indolent to an aggressive type, with local recurrence or distant metastasis. We herein report the case of a patient who was diagnosed with early-stage BCC of the prostate and treated by surgery. A 68 year-old-man visited our hospital for a follow-up for bladder cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/mco.2018.1754DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313957PMC
January 2019
1 Read

Primary urothelial carcinoma of the prostate: A rare case report.

Medicine (Baltimore) 2019 Jan;98(3):e14155

Department of Urology, The First Affiliated Hospital of Anhui Medical University.

Rationale: Prostatic urothelial carcinoma is a rare disease. Medical misdiagnosis rates remain high because there are no specific clinical symptoms or imaging features, which decreases patient survival. We report a case of prostatic urethral cancer confirmed by transrectal ultrasound-guided prostate biopsy because of an abnormal digital rectal exam. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014155DOI Listing
January 2019
1 Read
5.723 Impact Factor

Current Trends in Cancer Nanotheranostics: Metallic, Polymeric, and Lipid-Based Systems.

Pharmaceutics 2019 Jan 8;11(1). Epub 2019 Jan 8.

iMedUlisboa, Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal.

Theranostics has emerged in recent years to provide an efficient and safer alternative in cancer management. This review presents an updated description of nanotheranostic formulations under development for skin cancer (including melanoma), head and neck, thyroid, breast, gynecologic, prostate, and colon cancers, brain-related cancer, and hepatocellular carcinoma. With this focus, we appraised the clinical advantages and drawbacks of metallic, polymeric, and lipid-based nanosystems, such as low invasiveness, low toxicity to the surrounding healthy tissues, high precision, deeper tissue penetration, and dosage adjustment in a real-time setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/pharmaceutics11010022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6359642PMC
January 2019
1 Read

A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC).

Mol Imaging Biol 2019 Jan 7. Epub 2019 Jan 7.

Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.

Metastatic renal cell carcinoma (mRCC) is a disease that portends poor prognosis despite an increasing number of novel systemic treatment options including new targeted therapies and immunotherapy. Ablative intervention directed at oligometastatic RCC has demonstrated survival benefit. Consequently, developing techniques for improved staging of mRCC on contemporary imaging modalities including X-ray computed tomography (CT), magnetic resonance imaging (MRI) and/or bone scan (BS) is a clinical priority. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11307-018-01307-0DOI Listing
January 2019

Overexpression of prostate specific membrane antigen by canine hemangiosarcoma cells provides opportunity for the molecular detection of disease burdens within hemorrhagic body cavity effusions.

PLoS One 2019 2;14(1):e0210297. Epub 2019 Jan 2.

Department of Veterinary Clinical Medicine, University of Illinois, Urbana, IL, United States of America.

Background: Canine hemangiosarcoma (cHSA) is a highly metastatic mesenchymal cancer that disseminates by hematogenous and direct implantation routes. Therapies for cHSA are generally ineffective, in part due to advanced clinical disease stage at the time of diagnosis. The validation of conventional molecular methods for detecting novel biomarkers preferentially expressed by cHSA could lead to more timely diagnosis, earlier therapeutic interventions, and improved outcomes. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0210297PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314605PMC
January 2019
1 Read

Clear cell papillary renal cell carcinoma: A case report and review of the literature.

World J Nephrol 2018 Dec;7(8):155-160

Department of Urology, Center for Prostate Cancer, National Cancer Center, Goyang 410-769, South Korea.

Clear cell papillary renal cell carcinoma (ccpRCC) was recently established as a distinct type of epithelial neoplasm by the International Society of Urological Pathology Vancouver Classification of Renal Neoplasia. Here, we report a case of partial nephrectomy for a ccpRCC detected during the routine follow-up of a previously treated liposarcoma in a 70-year-old male patient. The patient was referred to the urology department for a right-sided renal mass (size: 2 cm) detected during routine annual imaging follow-up for a malignant right inguinal fibrous histocytoma and liposarcoma that had been diagnosed 6 and 4 years earlier, respectively, and treated with surgery and adjuvant radiation therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5527/wjn.v7.i8.155DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305527PMC
December 2018
1 Read

18F-choline PET/CT incidental thyroid uptake in patients studied for prostate cancer.

Endocrine 2018 Dec 29. Epub 2018 Dec 29.

Nuclear Medicine, University of Brescia and Spedali Civili Brescia, Brescia, Italy.

Purpose: Thyroid incidental uptake is defined as a thyroid uptake incidentally detected by imaging examinations performed for non-thyroid disease. The aim of this study was to establish the prevalence and the pathological nature of focal thyroid incidental uptake (FTIU) among patients studied with 18F-choline-PET/CT.

Materials And Methods: We retrospectively evaluated 368 patients who performed 18F-choline-PET/CT between June 2016 and August 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12020-018-01832-6DOI Listing
December 2018
2 Reads

Intraductal carcinoma of the prostate (IDC-P) lowers apparent diffusion coefficient (ADC) values among intermediate risk prostate cancers.

J Magn Reson Imaging 2018 Dec 25. Epub 2018 Dec 25.

Department of Medical Imaging, Ottawa Hospital, Ottawa, Ontario, Canada.

Background: Prostatic intraductal carcinoma (IDC-P) is an aggressive variant of prostate cancer (PCa) characterized by proliferation of malignant cells within prostatic ducts/acini and nucleomegaly.

Purpose/hypothesis: To compare apparent diffusion coefficient (ADC) values and Prostate Imaging and Data Reporting System (PI-RADS) v. 2 scores in intermediate risk (International Society of Urological Pathology [ISUP] Grade Group [GG] 2 and 3) PCa with/without IDC-P to determine if IDC-P alters the MRI appearance of PCa. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jmri.26594DOI Listing
December 2018
7 Reads
3.210 Impact Factor

Comparing diagnostic accuracy of luminal water imaging with diffusion-weighted and dynamic contrast-enhanced MRI in prostate cancer: A quantitative MRI study.

NMR Biomed 2019 Feb 21;32(2):e4048. Epub 2018 Dec 21.

UBC MRI Research Center, Vancouver, BC, Canada.

Luminal water imaging (LWI) is a new MRI T mapping technique that has been developed with the aim of diagnosis of prostate carcinoma (PCa). This technique measures the fractional amount of luminal water in prostate tissue, and has shown promising preliminary results in detection of PCa. To include LWI in clinical settings, further investigation on the accuracy of this technique is required. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/nbm.4048DOI Listing
February 2019

Prostate cancer laparoscopic port site metastasis: A case report.

Medicine (Baltimore) 2018 Dec;97(51):e13757

Introduction: Laparoscopic port site metastases are a rare but clinically important cause of biochemically recurrent prostate adenocarcinoma. C-11 choline, among other prostate-specific positron emission tomography (PET) radiotracers, has improved radiologist confidence in these otherwise difficult-to-detect sites of recurrence.

Patient Concerns: A 62-year-old male presented with biochemically recurrent prostate adenocarcinoma after undergoing robotic-assisted radical prostatectomy 5 years earlier. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000013757DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319866PMC
December 2018
1 Read

Management of Older Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scenario.

J Adv Pract Oncol 2018 Jan-Feb;9(1):67-76. Epub 2018 Jan 1.

Duke Prostate Center, Durham, North Carolina.

Tom, a 75-year-old white male, was recently diagnosed with metastatic renal cell carcinoma (RCC; Tom's case is not an actual clinical case but has been developed by the authors as an exemplar). Two years prior, he had undergone a left partial (laparoscopic) nephrectomy for clear cell RCC. At that time, he had a stage 3 disease (the tumor extended into perinephric tissues but not into the ipsilateral adrenal gland and not beyond Gerota's fascia [Cancer. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296420PMC
January 2018
2 Reads

Direct comparison of choline PET/CT and MRI in the diagnosis of lymph node metastases in patients with prostate cancer.

Medicine (Baltimore) 2018 Dec;97(50):e13344

Department of Nuclear Medicine, Pingjin Hospital, Characteristic Medical Center of Chinese People's Armed Police Forces, Tianjin, China.

Background: Lymph node detection in prostate cancer is challenging and critical to determine treatment policy. Choline PET/CT (positron emission tomography/computed tomography) and magnetic resonance imaging (MRI) have been used for the evaluation of lymph node metastasis in patients with prostate cancer for the past decade. However, only limited patients underwent direct comparison studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000013344DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320103PMC
December 2018
5.723 Impact Factor

Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies.

Urology 2018 Dec 12. Epub 2018 Dec 12.

Department of Urology, Yale School of Medicine, New Haven, CT. Electronic address:

Objective: To assess the association between Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) score, the Decipher score, and histologic grade of carcinoma in biopsy tissue among low- to intermediate-risk prostate cancer patients.

Methods: MRI-ultrasound targeted biopsy of regions of interest and concurrent 12-core systematic biopsy was performed on men with Gleason grade group (GG) 1 and 2. We compared Decipher score with PI-RADS scores and biopsy Gleason GG. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2018.12.001DOI Listing
December 2018
1 Read

Synthesis and SAR of novel capsazepine analogs with significant anti-cancer effects in multiple cancer types.

Bioorg Med Chem 2019 Jan 29;27(1):208-215. Epub 2018 Nov 29.

Department of Comprehensive Dentistry, University of Texas Health Science Center at San Antonio School of Dentistry, San Antonio, Texas 78229, USA; Mays Cancer Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA. Electronic address:

We previously demonstrated that capsazepine (CPZ), a synthetic transient receptor potential Vanilloid subtype 1 (TRPV1) antagonist, has significant anti-cancer effects in vivo. The purpose of this study was to develop more potent analogs based upon CPZ pharmacophore and structure-activity relationships (SAR) across analogs. We generated 30 novel compounds and screened for their anti-proliferative effects in cultured HeLa cervical cancer cells. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09680896183133
Publisher Site
http://dx.doi.org/10.1016/j.bmc.2018.11.040DOI Listing
January 2019
2 Reads
2.793 Impact Factor

Advances in Prostatic Diagnostics in Dogs: The Role of Canine Prostatic Specific Esterase in the Early Diagnosis of Prostatic Disorders.

Top Companion Anim Med 2018 Dec 8;33(4):105-108. Epub 2018 Sep 8.

Dipartimento di Medicina Veterinaria (DiMeV), Section of Surgery and Obstetrics, University of Bari Aldo Moro, Italy. Electronic address:

In last years, following the increased canine life expectancy and the rising attention pet-owners devote to their animals, several authors have carried on investigations concerning new techniques to early identify canine prostatic disorders that might affect the dog's quality of life. Prostatic disorders often have an asymptomatic onset and their early diagnosis is difficult: hence, they are usually identified at an advanced stage, only. Traditionally, the diagnosis of prostatic disorders is based on noninvasive tools, such as transrectal and abdominal palpation, seminal or prostatic fluid evaluation, and urinalysis and imaging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.tcam.2018.09.002DOI Listing
December 2018
1 Read

Comparison of biparametric MRI to full multiparametric MRI for detection of clinically significant prostate cancer.

Prostate Cancer Prostatic Dis 2018 Nov 9. Epub 2018 Nov 9.

Department of Urology, University of Alabama at Birmingham, Birmingham, AL, USA.

Background: Multiparametric magnetic resonance imaging (MP-MRI) and MRI/ultrasound (US) fusion-guided biopsy are becoming more widely used techniques for prostate cancer (PCa) diagnosis and management. However, their widespread adoption and use, where available, are limited by cost and added time. These limitations could be minimized if a biparametric MRI (BP-MRI) focusing on T2-weighted and diffusion-weighted imaging is performed. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41391-018-0107-0
Publisher Site
http://dx.doi.org/10.1038/s41391-018-0107-0DOI Listing
November 2018
8 Reads

Images in two prostate cancer patients of second primary cancers: Hodgkin's lymphoma and lung adenocarcinoma.

Hell J Nucl Med 2018 Sep-Dec;21(3):221-223. Epub 2018 Nov 10.

Nuclear Medicine Department, Greater Poland Cancer Centre, Garbary 15 Street, 60-101 Poznan, Poland.

Hodgkin's lymphoma and lung adenocarcinoma as second primary cancers in prostate cancer (PC) patients although are rare should be considered as important for the future of the PC patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1967/s002449910908DOI Listing
February 2019

Comparison of hock- and footpad-injection as a prostate adenocarcinoma model in rats.

BMC Vet Res 2018 Nov 6;14(1):327. Epub 2018 Nov 6.

Clinic of Diagnostic Imaging, Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 260, 8057, Zurich, Switzerland.

Background: Objective of this study is a feasibility-test comparing hock- and footpad-injection in rats with inoculated MatLyLu - adenocarcinoma tumor model. This study compares the development of an adenocarcinoma model (MatLyLu) in 12 Copenhagen rats. Two groups (n = 6) of animals were inoculated with 1 × 10 MatLyLu tumor cells solved in 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12917-018-1659-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219108PMC
November 2018

Computed tomography and magnetic resonance imaging findings of metastatic rectal linitis plastica from prostate cancer: A case report and review of literature.

World J Clin Cases 2018 Oct;6(12):554-558

Department of Surgery, Chonbuk National University Medical School and Hospital, Jeonju 54907, Chonbuk, South Korea.

Linitis plastica is a rare condition showing circumferentially infiltrating intramural anaplastic carcinoma in a hollow viscus, resulting in a tissue thickening of the involved organ as constricted, inelastic, and rigid. While most secondary rectal linitis plastica (RLP) is caused by metastasis from stomach, breast, gallbladder, or bladder cancer, we report an extremely rare and unique case of secondary RLP due to prostate cancer with computed tomography (CT) and magnetic resonance imaging (MRI) findings, including diffusion weighted imaging (DWI). A 78-year-old man presented with approximately a 2-mo history of constipation and without cancer history. Read More

View Article

Download full-text PDF

Source
http://www.wjgnet.com/2307-8960/full/v6/i12/554.htm
Publisher Site
http://dx.doi.org/10.12998/wjcc.v6.i12.554DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6212608PMC
October 2018
11 Reads

Discovery of F-JK-PSMA-7, a novel PET-probe for the detection of small PSMA positive lesions.

J Nucl Med 2018 Nov 2. Epub 2018 Nov 2.

University Hospital of Cologne, Germany.

Prostate specific membrane antigen (PSMA) expressed by the vast majority of prostate cancers (PCa) is a promising target for PCa imaging. The application of PSMA specific F-labeled PET probes like F-DCFPyL and F-PSMA-1007 considerably improved the accuracy of PCa tumor detection. However, there remains a need for further improvements regarding sensitivity and specificity. Read More

View Article

Download full-text PDF

Source
http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.118.218
Publisher Site
http://dx.doi.org/10.2967/jnumed.118.218495DOI Listing
November 2018
13 Reads
6.160 Impact Factor

Sorafenib-induced Prostate Volume Reduction, a New Adverse Effect Detected by Imaging: A Pilot Study.

J Belg Soc Radiol 2018 Oct 26;102(1):69. Epub 2018 Oct 26.

University of Tsukuba, Faculty of Medicine, Department of Diagnostic and Interventional Radiology, Ibaraki, JP.

Background: Sorafenib has been used in the treatment of advanced hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC). Sorafenib-associated organ reduction have been reported on imaging, such as thyroid, pancreas and muscle, but there has been no research on prostate volume reduction (PVR).

Methods: We retrospectively analyzed 26 patients (twenty with HCC and six patients with RCC) who underwent sorafenib therapy for 31 to 1225 days (median, 100 days). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5334/jbsr.1607DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208293PMC
October 2018
7 Reads

[A Case of Rectal Colon Cancer with Paraneoplastic Cerebellar Degeneration].

Gan To Kagaku Ryoho 2018 Oct;45(10):1510-1512

Dept. of Gastrointestinal Tract Surgery, Fukushima Medical University.

A case complicated with colorectal and prostate cancers in paraneoplastic(subacute)cerebellar degeneration(PCD)is extremely rare. We report a retrospective case of rectal carcinoma with paraneoplastic cerebellar degeneration. A 79-year-old man with Parkinson's disease was unable to walk because of paralysis. Read More

View Article

Download full-text PDF

Source
October 2018
20 Reads

Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinoma.

Br J Cancer 2018 Oct 31;119(9):1118-1128. Epub 2018 Oct 31.

Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, SW7 3RP, United Kingdom.

Background: AKT is commonly overexpressed in tumours and plays an important role in the metabolic reprogramming of cancer. We have used magnetic resonance spectroscopy (MRS) to assess whether inhibition of AKT signalling would result in metabolic changes that could potentially be used as biomarkers to monitor response to AKT inhibition.

Methods: Cellular and metabolic effects of the allosteric AKT inhibitor MK-2206 were investigated in HT29 colon and PC3 prostate cancer cells and xenografts using flow cytometry, immunoblotting, immunohistology and MRS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-018-0242-3DOI Listing
October 2018
4 Reads

Distinct Imaging Characteristics of Different Metastases From Primary Prostate Adenocarcinoma and Rectal Carcinoid Tumor on 18F-Fluciclovine and 68Ga-DOTATATE PET/CT.

Clin Nucl Med 2019 Jan;44(1):83-84

Department of Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

A 71-year-old man with history of prostate cancer is evaluated for rising prostate-specific antigen. The patient also has a history of rectal well-differentiated neuroendocrine tumor. On F-fluciclovine PET/CT, 2 retroperitoneal lymph nodes exhibited intense fluciclovine avidity, whereas one enlarged perirectal lymph node only showed background uptake. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00003072-900000000-9740
Publisher Site
http://dx.doi.org/10.1097/RLU.0000000000002358DOI Listing
January 2019
9 Reads

[Classification of Clinical Syndromes Associated with Skull-Base Metastasis in the MR Era].

No Shinkei Geka 2018 Oct;46(10):865-873

Division of Neurosurgery, Shizuoka Cancer Center.

Background: Skull-base metastases frequently cause progressive ipsilateral disturbances of cranial nerves or pain, resulting in poor quality of life in patients with cancer. Magnetic resonance(MR)imaging is the method to detect skull-base metastases, which demonstrates focal lesions of low-intensity signal and enhancement on T1-weighted MR images.

Methods: We reviewed clinical data and MR images from 127 patients with skull-base metastases diagnosed at Shizuoka Cancer Center Hospital between August 2012 and November 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11477/mf.1436203829DOI Listing
October 2018
11 Reads

[The Usefulness of 11C-Choline PET/CT for Detecting Metastasis and Treatment Monitoring of Renal Cell Carcinoma : Report of Two Cases].

Hinyokika Kiyo 2018 Aug;64(8):339-343

The Department of Radiology, Hyogo College of Medicine.

Although fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) has been widely used as a powerful tool in clinical oncologic imaging, its application in urological malignancies is limited. Recently, choline PET/CT has been successfully used for prostate cancer restaging. Here, we report the utility of choline PET/CT for the detection and monitoring of metastatic disease in two cases of renal cell carcinoma (RCC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14989/ActaUrolJap_64_8_339DOI Listing
August 2018
7 Reads

Initial experience with dual-energy computed tomography-guided bone biopsies of bone lesions that are occult on monoenergetic CT.

Skeletal Radiol 2019 Apr 20;48(4):605-613. Epub 2018 Oct 20.

Department of Radiology, Northwestern University Feinberg School of Medicine, 676 North Saint Clair Street, Suite 800, Chicago, IL, 60611, USA.

Objective: Our purpose was to determine whether dual-energy CT (DECT), specifically the bone marrow setting of the virtual noncalcium (VNCa) algorithm, could be used to identify and accurately biopsy suspected bone malignancies that were visible on magnetic resonance imaging (MRI), nuclear bone scintigraphy, or positron-emission tomography/computed tomography (PET/CT), but occult on monoenergetic computed tomography (CT) by virtue of being either isodense or nearly isodense to surrounding normal bone.

Materials And Methods: We present 4 cases in which DECT was used to detect various malignant bone lesions and was successfully used to direct percutaneous DECT-guided bone biopsies.

Results: Two of the lesions were solid tumor metastases (breast and prostate carcinoma), whereas two others were hematological malignancies (leukemia and lymphoma). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00256-018-3087-1
Publisher Site
http://dx.doi.org/10.1007/s00256-018-3087-1DOI Listing
April 2019
8 Reads

18F-FDG, 68Ga-DOTATATE and 68Ga-PSMA Positive Metastatic Large Cell Neuroendocrine Prostate Tumor.

Clin Nucl Med 2019 Jan;44(1):53-54

Department of Nuclear Medicine, Dokuz Eylul University, School of Medicine, Izmir, Turkey.

Prostate large cell neuroendocrine tumor is a rare disease. In this case, metastatic areas showing FDG uptake, somatostatin receptor positivity, and PSMA expression are shown in F-FDG PET/CT, Ga-DOTATATE PET/CT, and Ga-PSMA PET/CT in a 70-year-old man with the diagnosis of prostate large cell neuroendocrine carcinoma. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00003072-900000000-9741
Publisher Site
http://dx.doi.org/10.1097/RLU.0000000000002322DOI Listing
January 2019
9 Reads

Diagnostic Value of F-FDG PET/CT in Patients with Carcinoma of Unknown Primary

Mol Imaging Radionucl Ther 2018 Oct;27(3):126-132

Adnan Menderes University Faculty of Medicine, Department of Nuclear Medicine, Aydın, Turkey

Objective: The aim of this study is to investigate the clinical role of F-fluorodeoxyglucose (F-FDG) positron emission tomography/computed tomography (PET/CT) in patients with carcinoma of unknown primary (CUP).

Methods: One hundred twenty one patients with a diagnosis of CUP who underwent whole body F-FDG PET/CT imaging were included in this retrospective study. The final diagnoses were confirmed either histopathologically or by clinical follow-up. Read More

View Article

Download full-text PDF

Source
http://cms.galenos.com.tr/Uploads/Article_19780/MIRT-27-126-
Publisher Site
http://dx.doi.org/10.4274/mirt.64426DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6191738PMC
October 2018
10 Reads

Correlation between MR spectroscopy and histology in detection of prostatic carcinoma.

J Pak Med Assoc 2018 Jul;68(7):986-989

The Agha Khan University Hospital, Karachi, Pakistan.

Objective: To determine the diagnostic accuracy of magnetic resonance spectroscopy in the detection of prostatic carcinoma.

Methods: This descriptive, cross-sectional study was conducted at the Jinnah Postgraduate Medical Centre, Karachi, from July 24, 2014, to January 23, 2015, and comprised patients who had been screened for prostate cancer. Using non-probability purposive sampling, all magnetic resonance spectroscopy scans were interpreted by three radiologists. Read More

View Article

Download full-text PDF

Source

Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage.

Science 2018 10;362(6410):91-95

Department of Microbiology, Immunology, and Molecular Genetics, University of California-Los Angeles, Los Angeles, CA 90095, USA.

The use of potent therapies inhibiting critical oncogenic pathways active in epithelial cancers has led to multiple resistance mechanisms, including the development of highly aggressive, small cell neuroendocrine carcinoma (SCNC). SCNC patients have a dismal prognosis due in part to a limited understanding of the molecular mechanisms driving this malignancy and the lack of effective treatments. Here, we demonstrate that a common set of defined oncogenic drivers reproducibly reprograms normal human prostate and lung epithelial cells to small cell prostate cancer (SCPC) and small cell lung cancer (SCLC), respectively. Read More

View Article

Download full-text PDF

Source
http://www.sciencemag.org/lookup/doi/10.1126/science.aat5749
Publisher Site
http://dx.doi.org/10.1126/science.aat5749DOI Listing
October 2018
7 Reads

68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma.

Clin Nucl Med 2018 Dec;43(12):e422-e427

From the Clinic of Nuclear Medicine, and.

Introduction: Prostate-specific membrane antigen (PSMA) ligand PET/CT is an emerging modality to detect the metastatic disease, especially in intermediate- and high-risk prostate cancer (PCa). In this study, we analyzed the contribution of Ga-PSMA-11 PET/CT in staging and therapy management of newly diagnosed PCa.

Materials And Methods: A total of 78 patients with biopsy-proven PCa who were referred for Ga-PSMA-11 PET/CT for primary staging were retrospectively analyzed. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00003072-900000000-9744
Publisher Site
http://dx.doi.org/10.1097/RLU.0000000000002289DOI Listing
December 2018
11 Reads

68Ga-Prostate-Specific Membrane Antigen PET/CT and 18F-FDG PET/CT of Primary Signet Ring Cell Breast Adenocarcinoma.

Clin Nucl Med 2018 Nov;43(11):e414-e416

General Surgery Post Graduate Institute of Medical Education and Research, Chandigarh, India.

Primary signet ring cell adenocarcinoma of the breast is a rare neoplasm. Similar to other mucinous neoplasms, it has low FDG avidity and poor prognosis compared with the traditional ductal/lobular carcinomas. We present a case of a 40-year-old woman with signet ring cell adenocarcinoma and skeletal fluorosis showing higher uptake of Ga-prostate-specific membrane antigen in the primary lesion and the metastatic sites compared with F-FDG on PET/CT imaging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000002265DOI Listing
November 2018
2 Reads

Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study.

Eur J Nucl Med Mol Imaging 2019 01 19;46(1):129-138. Epub 2018 Sep 19.

Department of Nuclear Medicine, Steve Biko Academic Hospital, University of Pretoria, Private Bag X169, Pretoria, 0001, South Africa.

Background: A remarkable therapeutic efficacy has been demonstrated with Ac-prostate-specific membrane antigen (PSMA)-617 in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients. We report our experience with Ac-PSMA-617 therapy in chemotherapy-naïve patients with advanced metastatic prostate carcinoma.

Methods: Seventeen patients with advanced prostate cancer were selected for treatment with Ac-PSMA-617 in 2-month intervals, with initial activity of 8 MBq, then de-escalation to 7 MBq, 6 MBq or 4 MBq in cases of good response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4167-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267694PMC
January 2019
24 Reads
5.383 Impact Factor

Case 258: Granulomatous Prostatitis.

Radiology 2018 Oct;289(1):267-271

From the Departments of Radiology (A.D.d.L., D.N.C., I.P.), Urology (I.P.), and Pathology (F.F.), and the Advanced Imaging Research Center (D.N.C., I.P.), University of Texas Southwestern Medical Center, 2201 Inwood Rd, 2nd Floor, Suite 202, Dallas, TX 75390-9085.

History A 68-year-old man with a remote history of a previously resected high-grade urothelial carcinoma in the renal pelvis was being observed and was undergoing urologic treatment for recurrent low-grade urothelial carcinoma of the bladder. During his most recent evaluation, he reported no specific symptoms and denied experiencing hematuria, dysuria, or abdominal pain. At routine surveillance MRI of the abdomen and pelvis (images not shown), a lesion was noted in the peripheral zone of the prostate gland. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2018161272DOI Listing
October 2018
11 Reads

18F‑alfatide positron emission tomography may predict anti‑angiogenic responses.

Oncol Rep 2018 Nov 10;40(5):2896-2905. Epub 2018 Sep 10.

Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, Shandong 250117, P.R. China.

As the crucial issue in the development of anti‑angiogenic drugs is how to predict which patients will and will not benefit prior to the initiation of therapy, angiogenic 18F‑alfatide positron emission computed tomography (PET) was assessed in the present study. Lung adenocarcinoma A549 (high angiogenesis) and prostate PC‑3 (low angiogenesis) cell xenografted tumor‑bearing mice underwent 18F‑alfatide PET at baseline and following treatment with either an anti‑angiogenic therapy or vehicle. The evaluation index for the inhibition of tumor growth in the individuals in the treated groups was represented by treatment/control (T/C) ratio (%). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/or.2018.6692DOI Listing
November 2018
1 Read

Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [F]DCFPyL PET/CT.

Mol Imaging Biol 2018 Sep 14. Epub 2018 Sep 14.

The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Purpose: To investigate the utility of prostate-specific membrane antigen (PSMA)-targeted [F]DCFPyL positron emission tomography (PET)/X-ray computed tomography (CT) imaging for the detection of sites of disease in patients with metastatic non-clear cell renal cell carcinoma (RCC).

Procedures: Eight patients with metastatic non-clear cell RCC underwent imaging with PSMA-targeted [F]DCFPyL PET/CT. Imaged RCC histologic subtypes included papillary RCC (n = 3), chromophobe RCC (n = 2), unclassified RCC (n = 2), and Xp11 translocation RCC (n = 1). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11307-018-1271-2DOI Listing
September 2018
11 Reads

Gallium 68-PSMA PET/CT for lesion characterization in suspected cases of prostate carcinoma.

Nucl Med Commun 2018 Nov;39(11):1013-1021

Department of Gynec-Oncology, KIMS Hospital, Trivandrum.

Objective: To assess the feasibility of gallium 68 (Ga)-prostate specific membrane antigen (PSMA) PET/computed tomography (CT) to identify patients who truly harbor clinically significant prostate cancer (PCa) in a cohort of patients with clinical and biochemical/radiological suspicion of PCa.

Patients And Methods: A total of 118 patients with suspected PCa who underwent Ga-PSMA PET/CT between May 2015 and June 2016 were prospectively included. Final decision on performing biopsy was left to the referring urologist after considering the clinical data, scan findings and discussion with the patient. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MNM.0000000000000906DOI Listing
November 2018
1 Read

Incidental bladder cancers found on multiparametric MRI of the prostate gland: a single center experience.

Diagn Interv Radiol 2018 Sep;24(5):316-320

Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

Purpose: In the era of multiparametric magnetic resonance imaging (mpMRI) of the prostate gland, incidental findings are occasionally discovered on imaging. We aimed to report our experience of detecting incidental bladder cancers on mpMRI of the prostate in asymptomatic patients without irritative voiding symptoms or microscopic or gross hematuria.

Methods: A retrospective review was performed on a prospectively maintained database of all men who underwent prostate mpMRI at our institution from 2012 to 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5152/dir.2018.18102DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135055PMC
September 2018
7 Reads

Effect of androgen deprivation and radiation therapy on MRI fiber tractography in prostate cancer: can we assess treatment response on imaging?

Br J Radiol 2018 Sep 21:20170170. Epub 2018 Sep 21.

1 Department of Radiology, Division of Abdominal Imaging, Massachusetts General Hospital , Boston, MA , USA.

Objective:: To evaluate quantitative changes in Diffusion Tensor Magnetic Resonance Tractography in prostate cancer following androgen deprivation and radiation therapy.

Methods:: 22 patients with elevated PSA and biopsy proven prostate carcinoma who underwent MRI of the prostate at 1.5 T with an endorectal coil were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1259/bjr.20170170DOI Listing
September 2018
1 Read

Hybrid imaging PET/MR in prostatic carcinoma.

Cas Lek Cesk 2018 ;157(4):169-174

Imaging of the own prostatic tissue is being not easy using standard tumour imaging approaches, contrast enhanced computed tomography and the hybrid imaging using PET/CT with the application of the 18F-fluorodeoxyglucose. Magnetic resonance imaging is useful in detection of the patients with the elevated prostatic specific antigen (PSA) and/or with the increased index of the health prostate index (PHI). The novel imaging possibilities of the imaging is hybrid positron emission tomography - magnetic resonance imaging (PET/MR) with the application of 18F-fluorocholine (FCH), 18F-natriumfluoride (18F-NaF) or 68Ga-PSMA-11 (ligand of prostatic specific membrane antigen) in detection, staging or restaging of the prostatic carcinoma. Read More

View Article

Download full-text PDF

Source
January 2018
10 Reads

Hepatic Metastases From Prostatic Adenocarcinoma Without Elevated 18F-Choline Activity.

Clin Nucl Med 2018 Oct;43(10):780-781

We report the case of a 69-year-old man referred for F-fluorocholine (FCH) PET/CT for a biochemical recurrence of prostate cancer. FCH PET/CT demonstrated 2 hypodense hepatic lesions with no uptake but progressing in size compared with a previous assessment. MRI showed a suspicious peripheral contrast enhancement, raising the question of a liver metastasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000002254DOI Listing
October 2018
17 Reads